|
業務類別
|
Biotechnology |
|
業務概覽
|
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing. |
| 公司地址
| 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 415 910-5717 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.quincetx.com |
| 員工數量
| 38 |
| Dr. Brigette Roberts, M.D. |
Chief Executive Officer, Director and Chief, Corporate Affairs |
-- |
09/10/2026 |
| Mr. John Militello, C.P.A. |
Chief Financial Officer |
-- |
09/10/2026 |
| Dr. Keith R. Fandrick, PhD |
Chief Operating Officer |
-- |
09/10/2026 |
|
|
| Dr. Brigette Roberts, M.D. |
Chief Executive Officer, Director and Chief, Corporate Affairs |
09/10/2026 |
| Ms. Leone D Patterson, M.B.A. |
Director |
09/10/2026 |
| Mr. Drayton Wise |
Director |
09/10/2026 |
| Dr. Catherine M. Bonuccelli, M.D. |
Director |
09/10/2026 |
| Mr. James Valentine |
Director |
09/10/2026 |
|
|
|
|